Navigation Links
Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
Date:8/31/2011

CAMBRIDGE, Mass., Aug. 31, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), announced today that Idenix management will participate in a panel discussion at Citi's 6th Annual Biotech Day on September 7, 2011 at 10:00 a.m. ET at the Ritz Carlton, Boston, and present corporate overviews at the William Blair Life Sciences Conference on September 7, 2011 at 2:40 p.m. ET at the InterContinental New York Barclay, New York City and the Stifel Nicolaus Healthcare Conference on September 9, 2011 at 8:35 a.m. ET at the Four Seasons, Boston.

The live and archived webcasts of the company presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conferences.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter and Six Month 2011 Financial Results
2. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
3. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
4. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
7. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
11. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... BEACH, Calif. , July 28, 2015 /PRNewswire-USNewswire/ ... announced that it has hit a milestone of ... Signafuse was FDA 510(k) cleared in early 2014 ... use in posterolateral spine fusion procedures.  This is ... products, as less than 6% of new synthetic ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris ... announced that it has granted to German life ... the development and commercialization of biotechnology (collectively, the ... recombinant oral allogenic tumor vaccine technology (the "Technology"), ... prostate cancer which is ready to enter a ...
(Date:7/28/2015)... Israel , July 28, 2015 /PRNewswire/ ... regenerative medicine company utilizing its proprietary plant-based rhCollagen ... Shomrat Shurtz has been appointed Senior Director of ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... experience in marketing, regulatory and business strategy. Prior ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... Trade Name Will be ... Effient(TM), TOKYO ... Lilly and Company (NYSE: LLY ) today,announced that on Wednesday, Dec. ... U.S. Food and Drug Administration,(FDA). Prasugrel is an oral antiplatelet agent, initially ...
... ... Counsel-, -Gisela M. Schwab Promoted to Executive Vice President and Chief Medical ... Officer-, ... promotions for two members of its,senior management team. Pamela A. Simonton, Senior Vice President of,Patents ...
... to the pharmaceutical and biotechnology ... industries strengthens specialist expertise, BOSTON, Jan. 3 ... with a passion for research excellence,and a commitment to ... has joined the firm as Vice President. Dr. Hartman,s,research ...
Cached Biology Technology:Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 2Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 3Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration 4Exelixis Announces Senior Management Promotions 2Exelixis Announces Senior Management Promotions 3Observant LLC Expands Senior Management Team 2
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... ) has announced the addition of the ... their offering. To this date, fingerprint ... biometric technology and fingerprint sensors are well developed. ... capacitive sensing technology. The domain of ...
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... or tails venomous sea snakes in the Pacific and Indian Oceans ... published today in Marine Ecology . The discovery, ... that Yellow-lipped Sea Kraits ( Laticauda colubrina ) use skin markings ... a second head, complete with lethal venom. ...
... 2009 - It is important to understand what biological ... under conditions of extreme stress, such as those regularly ... A. Morgan III and his colleagues from Yale University ... closely with collaborators at the Special Forces Underwater Warfare ...
... in many areas of the United States, scientists in Minnesota ... the clean-burning energy source of the future may consume ... study appeared in ACS, journal Environmental Science & Technology ... study that annual bioethanol production in the U.S. is currently ...
Cached Biology News:Venomous sea snakes play heads or tails with their predators 2Venomous sea snakes play heads or tails with their predators 3Hormone levels contribute to stress resilience 2
SRY (sex determining region Y)-box 10...
Complement C1r [Human]...
biotin-4-fluorescein...
... LVF-CUV-ADP, FHS-LVF and CVD-Diffuse We've combined ... Filters to create the world's first notch ... adjustable bandpass. Each filter features an excellent ... These filters -- with interference coatings ...
Biology Products: